drugset / Trial / NCT00916604

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

NCT00916604

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.

Timeline

Start
2009-05
Primary completion
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral